Archive | Melanoma News

Targeted Drug Combination Can Have Long-Lasting Results for Some With BRAF-Mutated Melanoma

A personalized therapeutic cancer vaccine being developed by Elios Therapeutics for patients with high-risk melanoma demonstrated positive results in a phase 2b clinical trial, according to a press release.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Study finds genetic testing motivates behavior changes in families at risk for melanoma

Skin cancer is the most commonly diagnosed cancer in the United States, and melanoma is the most severe type of skin cancer.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

NCI awards $11 million grant to NYU Langone to develop immunotherapy biomarkers

NCI awarded a 5-year, $11 million grant to NYU Langone Health’s Ronald O. Perelman department of dermatology to develop biomarkers that can predict whether immunotherapy will be effective for specific patients.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Targeted Drug Combination Can Have Long-Lasting Results for Some With BRAF-Mutated Melanoma

For about half of patients with advanced melanoma, there is only one treatment choice: immunotherapy. But for those whose late-stage melanoma expresses a BRAF gene mutation, there’s another option – combinations of targeted drugs.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest